BioCryst Pharmaceuticals Inc banner

BioCryst Pharmaceuticals Inc
F:BO1

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
F:BO1
Watchlist
Price: 8.028 EUR -2.48% Market Closed
Market Cap: €1.7B

Wall St Price Targets

BO1 Price Targets Summary
BioCryst Pharmaceuticals Inc

Wall Street analysts forecast BO1 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BO1 is 13.9 EUR with a low forecast of 8.4 EUR and a high forecast of 21.497 EUR.

Lowest Forecast
Price Target
8.4 EUR
5% Upside
Average Forecast
Price Target
13.9 EUR
73% Upside
Highest Forecast
Price Target
21.497 EUR
168% Upside
BioCryst Pharmaceuticals Inc Competitors:
Price Targets
CSGP
CoStar Group Inc
59% Upside
PRQR
ProQR Therapeutics NV
434% Upside
DXPE
DXP Enterprises Inc
-9% Downside

Revenue
Forecast

31% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
31% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 31%. The projected CAGR for the next 8 years is 9%.

Gross Profit
Forecast

31% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
31% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

Over the last 13 years, the compound annual growth rate for Gross Profit has been 31%. The projected CAGR for the next 8 years is 9%.

Operating Income
Forecast

N/A
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

The compound annual growth rate for Operating Income over the next 8 years is 10%.

Pre-Tax Income
Forecast

N/A
Past Growth
-7% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
-7% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

The compound annual growth rate for Pre-Tax Income over the next 3 years is -7%.

Net Income
Forecast

N/A
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

The compound annual growth rate for Net Income over the next 8 years is 20%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is BO1's stock price target?
Price Target
13.9 EUR

According to Wall Street analysts, the average 1-year price target for BO1 is 13.9 EUR with a low forecast of 8.4 EUR and a high forecast of 21.497 EUR.

What is the Revenue forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
9%

Over the last 13 years, the compound annual growth rate for Revenue has been 31%. The projected CAGR for the next 8 years is 9%.

What is the Gross Profit forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
9%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 31%. The projected CAGR for the next 8 years is 9%.

What is the Operating Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
10%

The compound annual growth rate for Operating Income over the next 8 years is 10%.

What is the Pre-Tax Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
-7%

The compound annual growth rate for Pre-Tax Income over the next 3 years is -7%.

What is the Net Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
20%

The compound annual growth rate for Net Income over the next 8 years is 20%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett